STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2323 by analyst upside · 2026-08-12
CORT
Corcept Therapeutics Incorporated
Healthcare · Market Cap $12B · P/E 248.6x
ANALYST PRICE TARGET
+20.9%
implied upside to consensus target
Current Price $111.86
Consensus Target $135.25
Bull Target $165.0
Bear Target $50.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
2
Hold
0
Sell
1
52-Week Low $28.66
52-Week High $122.21
YTD Return +192.8%
FUNDAMENTALS
Market Cap $12B
P/E Ratio (TTM) 248.6x
Forward P/E 24.8x
EPS (TTM) $0.45
PEG Ratio 0.81
Dividend Yield N/A
Revenue (TTM) $831M
Profit Margin 6.6%
52-WEEK RANGE
52-Week Low $28.66
52-Week High $122.21
Current Price $111.86
Bear Target $50.0
Bull Target $165.0
● Now $111.86 ● Target $135.25
TRADING DATA
Avg Volume 1.2M
YTD Return +192.8%
Analyst Count 4
Consensus Buy
Upside to Target +20.9%
Last Updated 2026-08-12

ANALYST SUMMARY

Corcept Therapeutics Incorporated (CORT) is currently trading at $111.86 with a Wall Street consensus price target of $135.25, implying potential upside of 20.9% over the next 12 months. 4 analysts currently cover CORT, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $165.0, while the most cautious has a target of $50.0.

CORT operates in the Healthcare sector with a market capitalisation of $12B. The stock is up 192.8% year-to-date and is currently trading near the upper end of its 52-week range of $28.66 – $122.21.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CORT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-05-28 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-28 31% win rate (48 calls)
UBS ↑ Upgrade
Neutral → Buy 2026-05-13 33% win rate (6 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-04 31% win rate (48 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-05-01 14% win rate (7 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-03-26 Building track record
Wolfe Research ↑ Upgrade
Underperform → Peer Perform 2026-03-26 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-25 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
35
out of 100
Coverage depth
12/30
Consensus clarity
9/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →